Gary Reuther: SHP2 may be a therapeutic target for patients with MPNs
Photo taken from healthcheckup.com

Gary Reuther: SHP2 may be a therapeutic target for patients with MPNs

Gary Reuther, Professor at Moffitt Cancer Center, shared on X:

“I am excited that our work, led by Garima Pandey, showing SHP2 may be a therapeutic target for patients with myeloproliferative neoplasms (MPNs) is officially published in American Journal of Hematology.

‘SHP2 inhibition displays efficacy as a monotherapy and in combination with JAK2 inhibition in preclinical models of myeloproliferative neoplasms‘

Authors: Garima Pandey, Lucia Mazzacurati, Tegan M. Rowsell, Nathan P. Horvat, Narmin E. Amin, Guolin Zhang, Afua A. Akuffo, Christelle M. Colin-Leitzinger, Eric B. Haura, Andrew T. Kuykendall, Ling Zhang, Pearlie K. Epling-Burnette, Gary W. Reuther.”

Gary Reuther

Source: Gary Reuther/X